











doi:10.101A Clinical Study of Cervical Dysplasia in Long-Term
Survivors of Allogeneic Stem Cell Transplantation
Yun Wang,1 Lorentz Brinch,2 Peter Jebsen,3 Tom Tanbo,1,4 Rolf Kirschner1This retrospective study examined the prevalence of and risk factors for cervical dysplasia and genital human
papillomavirus (HPV) infection in 89 female recipients of allogeneic stem cell transplantation (allo-SCT)
between 1985 and 2005 who survived for more than 5 years after transplantation. All patients underwent
regular gynecologic examination and cervical cytological testing. The incidence rates of cervical cytological
abnormalities and HPV infection were calculated. Various clinical parameters were evaluated for association
with cytological high-grade squamous intraepithelial lesion (HSIL) posttransplantation to identify risk factors
for cervical dysplasia. Multivariate analysis with logistic regression was used to identify independent risk
factors for cervical dysplasia after adjusting for confounding factors. Sixty-one of the 89 patients (68.5%)
had cervical cytological abnormalities of varying grades, including atypical squamous cells of undetermined
significance (ASC-US; 31.5%; 28 of 89), low-grade squamous intraepithelial lesion (LSIL; 10.1%; 9 of 89),
and HSIL (27%; 24 of 89). HPV status was available for 43 patients, 12 of whom (27.9%) were HPV-positive.
Among the 69 patients with normal cytological cervical smear findings pretransplantation, the incidence of
cytological HSIL was 23.2% (16 of 69) posttransplantation. After adjusting for confounding factors, only
unrelated HLA-matched donor and the presence of vulvovaginal chronic graft-versus-host disease (cGVHD)
were independent risk factors for cervical cytology HSIL after transplantation, with the highest risk among
patients with vulvovaginal cGVHD (adjusted odds ratio, 31.97). We conclude that long-term survivors of
allogeneic stem cell transplantation are at high risk for cervical cytological abnormalities. Vulvovaginal cGVHD
and unrelated HLA-matched donor were the only independent risk factors for cervical cytological HSIL in
patients with normal cervical cytology before transplantation. Regular surveillance by gynecologic examina-
tion, including cervical cytological testing, in these patients allows for early diagnosis and effectivemanagement
of cervical abnormality and decreases the burden of this potentially fatal, but treatable, condition.
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Invasive cervical cancer was diagnosed in approxi-
mately 9710 women and killed 3700 women in the
United States in 2006 [1]. Each year, approximately
300 women are diagnosed with cervical cancer in
Norway, and the overall mortality is approximately
30% (data from the Norwegian Cancer Registry
[NCR]; http://www.kreftregisteret.no/en/). Convinc-
ing evidence suggests that most cervical cancers are
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6/j.bbmt.2011.09.012(HPV), with high-risk HPV subtypes (16, 18, 31, 33,
and 35) accounting for.95% of cervical intraepithelial
neoplasia and invasive cancer [2,3]. In non-
immunosuppressed women, the mean age of onset of
cervical dysplasia is approximately 15 years earlier than
that of invasive cancer, suggesting a slow progression
of cervical dysplasia to invasive carcinoma [4].However,
in immunosuppressed women, the progression from
cervical dysplasia to invasive carcinoma is accelerated,
and cervical cancer is likely a more aggressive disease
[5]. Cervical cancer remains the most common cancer
in HIV-positive females in western Europe [6].
Allogeneic stem cell transplantation (allo-SCT)
offers a possibility of cure for patients with leukemia,
myeloproliferative and myelodysplastic syndromes,
lymphoma, and severe aplastic anemia. Almost 90%
of patients who are alive 2 years after allo-SCT will
become long-term survivors [7]. The care in this group
of patients has been extended from curing the primary
disease to identifying and treating long-term compli-
cations that might affect their quality of life. However,
long-term survival may be impaired by the onset of747
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cal, vaginal, vulvar, and perianal malignancies [9,10].
This may be linked to several risk factors, including
ionizing radiation and chemotherapy used for
pretransplantation conditioning and treatment of the
primary malignant disease, immunodeficiency due
to delayed and incomplete immune system recovery,
immune stimulation and immunosuppression by
graft-versus-host disease (GVHD), and prolonged
immunosuppressive therapy for chronic GVHD
(cGVHD). Indeed, a recent multi-institutional cohort
study of 28,874 allo-SCT recipients found that these
patients developed new solid cancers at twice the rate
expected based on the rate in the general population
(observed-to-expected ratio, 2.1; 95% confidence
interval [CI], 1.8-2.5), and that cGVHD and male
sex were the main determinants for risk of squamous
cell carcinomas [11].
Cervical cancer is reportedly the second most
common neoplasia after skin cancer in female renal
transplant recipients [2,12] and the third most
common in long-term survivors of allo-SCT [13].
This malignancy can be surveilled by screening tests
before and after transplantation. Although many stud-
ies have investigated the association between solid
organ transplantation and cervical neoplasia, few stud-
ies have focused on allo-SCT and cervical neoplasia
[14,15]. Moreover, most reports on cervical neoplasia
posttransplantation have involved either a limited
number of patients or short follow-up periods
[15,16]. Few reports studied risk factors for cervical
neoplasia among transplant recipients. One recent
study of 35 long-term survivors with a median
follow-up of 85 months found an 34% rate of post-
transplantation cervical dysplasia. Patients requiring
continued systemic immunosuppressive therapy for
GVHD for more than 3 years were at greatest risk [14].
The present study examined the prevalence of and
risk factors for cervical dysplasia and genital HPV
infection in long-term survivors of allo-SCT, with
the aim of improving surveillance and allowing early
diagnosis and effective management in the early stages
of this potentially fatal, but treatable, condition.MATERIALS AND METHODS
Patients and Data
This retrospective case series study evaluated the
prevalence of and risk factors for cervical dysplasia
and genital HPV infection in long-term survivors of
allo-SCT in our hospital, the sole transplantation cen-
ter in Norway. Norway’s Regional Committee for
Medical and Health Research Ethics (Reference
2010/98) and our hospital’s Institutional Review Board
approved the study protocol, and exemption from the
need for confidentiality was granted.We have consecutively registered all patients .15
years old who were treated with myeloablative condi-
tioning allo-SCT at the Department of Hematology,
Oslo University Hospital Rikshospitalet since 1985.
We limited our study to those patients who survived
at least 5 years posttransplantation, given the relatively
high mortality due to transplantation-related compli-
cations other than secondary malignant neoplasm
and recurrence of original disease in the first years after
allo-SCT. These causes of death may interfere in
a nonrandom manner with the development of malig-
nant neoplasms. All myeloablative conditioning allo-
SCTs for malignant diagnoses were performed after
conditioning with busulfan and cyclophosphamide,
except in 2 patients before 1989 who received total
body irradiation and cyclophosphamide. Patients
with severe aplastic anemia received cyclophospha-
mide plus equine antithymocyte globulin. All patients
received cyclosporine and methotrexate as prophylaxis
for acute GVHD (aGVHD), except 1 patient whose
bone marrow stem cells came from her genetic identi-
cal twin and thus received no prophylactic treatment.
Clinical information, including age at transplanta-
tion, hematologic diagnosis, donor and stem cell
sources, disease risk, conditioning therapy, and occur-
rence of aGVHD and cGVHD, was consecutively
registered in our hospital’s allo-SCT database. The
incidence and time to development of grade II-IV
aGVHD were evaluated in patients surviving 21 days
with evidence of engraftment [17]. Time to occurrence
of cGVHDwas evaluated in patients surviving 90 days
or longer with engraftment [18]. Medical records were
reviewed for all the patients to confirm the information
collected from the database and to provide more
clinical information before transplantation, such as
occurrence of vulvovaginal cGVHD [19], duration of
immunosuppressive therapy, marital status, smoking
history, menopause history, parity before transplanta-
tion, and hormone replacement therapy (HRT) after
transplantation. Gynecologic examination, including
assessment for vulvovaginal cGVHD, cervical cytol-
ogy testing (originally using the Papanicolau
technique, but from 2003 using liquid-based cytol-
ogy), and cervical viral and bacterial culture, was
performed in all patients as part of the routine workup
before allo-SCT in the patients who were $18 years
old or sexually active. We developed a clinical policy
(which is also the national guideline in Norway)
for follow-up care of these patients.We recommended
gynecologic examination within 3 months before
transplantation, every 3 months during the first year
posttransplantation, and once a year in the subsequent
4 years. Patients with normal cytological findings
thereafter were followed up in accordance with the
regular cervical cytological screening program (every
3 years in Norway), either by a gynecologist or by
the patient’s own general practitioner. The results of
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2001 Bethesda classification scheme as follows:
negative, atypical squamous cells of undetermined
significance (ASC-US), atypical glandular cells of un-
determined significance (AGUS), low-grade squamous
intraepithelial lesion (LSIL), high-grade squamous
intraepithelial lesion (HSIL), or adenocarcinoma in
situ (AIS).
Results of cervical biopsy analysis in patients with
repeated cytological HSIL within 3 months were
available as well. Grading of the epithelial abnormali-
ties was recorded according to the Bethesda classifica-
tion scheme and classified as cervical intraepithelial
neoplasia (CIN) I, II, or III; carcinoma in situ (CIS);
or AIS. Patients classified with ASC-US or LSIL
by cytological testing were also subjected to an
HPV-DNA test (Hybrid Capture II; Digene Corpora-
tion, Gaithersburg, MD). Those with a positive DNA
test underwent polymerase chain reaction subtyping
with an in-house method for high-risk types (HPV
DNA 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
and 69) from 2003. Patients classified with HSIL in
repeated tests within 3 months underwent colposcopy
and biopsy analysis to classify the grade of dysplasia.
Any patient found to have CIN II or worse underwent
treatment by conization or hysterectomy as indicated.
If abnormal test results were found, the earliest occur-
ring posttransplantation pathological result was used
in the analysis. Cytological and histological results
from these patients were available from our hospital
pathology database before and 5 years after trans-
plantation. All data on cervical cytological and
histological tests have been recorded in the NCR since
1992, and HPV status has been recorded in the NCR
since July 2005 (http://www.kreftregisteret.no/no/
Forebyggende/Masseundersokelsen-mot-livmorhalsk
reft/). Cytological and histological data from the NCR
were available for these patients up to August 2010. In
addition, we compared the proportion of abnormal
Pap smears in our study population with the incidence
of abnormal smears among age-matched women from
the general population in 2008 (data from the NCR).
The observation time for each patient using immuno-
suppressive drugs was calculated in months from the
day of transplantation until the most recent cervical
smear before August 2010.
Statistics
To identify risk factors for cervical dysplasia, the
proportion of cytological HSIL posttransplantation
was compared with the following clinical parameters:
age at transplantation, hematologic diagnosis, donor
source, stem cell source, disease risk, conditioning ther-
apy, aGVHD, cGVHD, vulvovaginal cGVHD, dura-
tion of immunosuppressive therapy, and duration
of follow-up. Age at transplantation, duration of
immunosuppressive therapy, and duration of follow-up were included as continuous variables. Other clinical
and transplantation characteristics were included as cat-
egorical variables: donor source (related HLA identical
or unrelated HLA-matched donor); hematopoietic
stem cell source source (bone marrow versus peripheral
blood); presence versus absence of GVHD (aGVHD,
cGVHD, and vulvovaginal cGVHD); and disease risk
(standard risk [patients in first complete remission of
acute leukemia and those in first chronic phase of
CML, myeloproliferative and myelodysplastic syn-
dromes, and severe aplastic anemia] versus high risk).
In the univariate analyses, the c2 or Fisher exact
test was used for categorical variables and the Mann-
Whitney U test was used for continuous variables.
Variables with a P value\.20 in the univariate analyses
were included in multivariate analysis. Multivariate
analysis with logistic regression was used to identify in-
dependent risk factors before and after adjusting for
confounding factors (marital status, smoking history,
menopause history, HRT, and parity before transplan-
tation). Statistical significance was accepted at P\ .05.
Data analyses were performed using SPSS version 16
for Windows (SPSS, Inc., Chicago, IL).RESULTS
Patient Characteristics
A total of 96 patients underwent allo-SCT between
November 1985 andNovember 2005 in our center and
were alive more than 5 years after transplantation. Five
patients who had undergone previous hysterectomies
and 2 patients who had not commenced sexual activity
were excluded; thus, the study group comprised 89
patients. The median age at transplantation was 39
years (range, 15-59 years). All but 1 patient were alive
as of November 2010. One patient died of recurrent of
chronic myelogenous leukemia at 6 years posttrans-
plantation. The median follow-up time was 11 years
(range, 5-25 years). Two patients with aplastic anemia
became pregnant and gave birth at 2 years and 3 years
after transplantation. The median duration of immu-
nosuppressive treatment was 12 months (range, 0-78
months). Clinical characteristics of the patients are
summarized in Table 1.
The most frequent indication for allo-SCT was
leukemia (92.1%), and 76.4% of the patients received
a transplant from a relatedHLA-matched donor. Acute
GVHDoccurred in 36 patients (40.4%), cGVHDin 40
patients (44.9%), and vulvovaginal cGVHD in 6 pa-
tients (6.7%). Three cases of secondary cancer (2 breast
cancers and 1 verrucous carcinoma in the jaw) were re-
ported at a median of 7 years after allo-SCT.
Incidence and Types of Cervical Abnormalities
Although our protocol recommended 9 gyneco-
logic examinations including cervical cytology testing
Table 1. Clinical Characteristics of the 89 Study Patients
Hematologic diagnosis, % (n)
Acute lymphoblastic leukemia 7.9 (7)
Acute myelogenous leukemia 40.4 (36)
Chronic myelogenous leukemia 43.8 (39)
Aplastic anemia 3.4 (3)
Myelodysplastic syndrome 2.3 (2)
Multiple myeloma 1.1 (1)
Diamond-Blackfan anemia 1.1 (1)
Married at time of SCT, % (n) 74.2 (66)
Smoking history, % (n) 41.6 (37)
Parity before SCT, % (n) 68.5 (61)
Menopause before SCT, % (n) 27 (24)
Menopause after SCT, % (n) 66.3 (59)
High risk for disease, % (n) 15.7 (14)
Unrelated HLA-matched donor, % (n) 23.6 (21)
Peripheral blood as stem cell source, % (n) 18 (16)
Conditioning therapy, % (n)
Cyclophosphamide + busulfan 93.2 (83)
Cyclophosphamide + total body irradiation 3.4 (3)
Cyclophosphamide + antithymocyte globulin 3.4 (3)
aGVHD, % (n) 40.4 (36)
cGVHD, % (n) 44.9 (40)
Vulvovaginal cGVHD, % (n) 6.7 (6)
Duration of immunosuppressive therapy, days, median (range) 12 (0-78)
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vical screening program was performed in only 11 of
the 89 patients (12.3%) during this period. The
mean number of cytology tests for each patient was
6.5 (range, 2-9).
Results of cervical smears performed within 3
months before transplantation were available for 79
of the 83 patients, with normal smears in 69 patients
and abnormal smears in 10 patients (11.2%) of various
grades, including 5 cases of ASC-US (6.3%), 3 cases of
LSIL (3.8%), and 2 cases of HSIL (2.5%). The mean
age of these 10 patients was 33.3 6 12.3 years (range,
15-52 years). Of the 5 patients with ASC-US before
transplantation, only 1 patient had progression to
HSIL at 6 months after transplantation. Of the 3 pa-
tients with LSIL, 1 patient progressed to HSIL by 1
year posttransplantation, and this patient underwent
3 conization procedures to treat persistent CIN III,
and then finally a hysterectomy at 5 years posttrans-
plantation. Another of these 3 patients developed
HSIL at 3 months posttransplantation and underwent
conization without later recurrence. The third of these
3 patients had no evidence of progressive cervical ab-
normalities after transplantation, but was diagnosed
with breast cancer at 8 years posttransplantation.
Among the 2 patients with HSIL before transplanta-
tion, 1 patient showed persistent HSIL at 3 monthsTable 2. Incidence of Post-SCT Cervical Abnormalities and HPV S
Total (n 5 89)
Pretransplantation Cervical Cytology
Normal (n 5 69) Abnormal (n 5 10) M
Normal, % (n) 31.5 (28) 36.2 (25) 0
ASC-US, % (n) 31.5 (28) 31.9 (22) 40 (4)
LSIL, % (n) 10.1 (9) 8.7 (6) 10 (1)
HSIL, % (n) 27 (24) 23.2 (16) 50 (5)and 6 months posttransplantation and underwent con-
ization without evidence of subsequent recurrence, but
the other patient developed persistentHSIL in the sec-
ond year after transplantation and underwent coniza-
tion at 4 years posttransplantation.
The total incidence of posttransplantation cervical
abnormalities is shown in Table 2. Sixty-one of the 89
patients (68.5%) had a cervical abnormality of varying
grade at some point in time, with a 31.5% incidence of
ASC-US (28 of 89), a 10.1% incidence of LSIL (9 of
89), and a 27% incidence of HSIL (24 of 89). The
mean age of these 61 patients with abnormal cervical
cytology was 37.7 6 12 years (range, 15-59 years).
Among the 69 patients with normal cytological cervi-
cal smears before transplantation, the incidence of
ASC-US, LSIL, and HSIL after transplantation was
31.9% (22 of 69), 8.7% (6 of 69), and 23.2% (16 of
69), respectively.
Fourteen women with repeated cytological HSIL
underwent cervical biopsy analysis. Eleven of these 14
(78.6%) had histologically verified cervical intraepithe-
lial neoplasia, including AIS in 1 patient, CIN II in 2
patients, andCIN III in 8 patients.No invasive cervical
carcinoma was found. The median time to develop-
ment of cytological HSIL and histologically verified
CIN II/CIN III/AIS was 6 months (range, 3-60
months) and 12 months (range, 5-60 months), respec-
tively. The final intervention consisted of successful
treatment with conization in 10 patients and hysterec-
tomy in 1 patient due to coexisting severe vulvovaginal
cGVHD with vaginal synechia, making follow-up
difficult.
Information on HPV status after transplantation
was available for 43 patients (Table 2), of whom 12
(27.9%) were HPV-positive and 31 (72.1%) were
HPV-negative. Twenty of the 28 recipients with
ASC-US were tested for HPV; 4 (20%) demonstrated
changes associated with HPV, and 16 (80%) had non-
specific (HPV-negative) changes. Six of the 9 recipients
with LSIL were tested for HPV, and all demonstrated
nonspecific changes. Twelve of the 24 recipients with
HSIL were tested for HPV; 7 (58.3%) had changes as-
sociated with HPV, and 5 (41.7%) had nonspecific
changes. Only 1 patient was positive for HPV without
coexisting cervical cytological abnormality. Four pa-
tients had HPV type 16 or 18 (3 with HSIL and 1
with ASCUS), 1 patient had HPV type 31, and the
other 7 patients had an unknown type of HPV.tatus
Results
HPV Status Available (n 5 43) HPV-Positive (n 5 12)issing (n 5 10)
30 (3) 11.6 (5) 8.3 (1)
20 (2) 46.6 (20) 33.3 (4)
20 (2) 13.9 (6) 0 (0)
30 (3) 27.9 (12) 58.3 (7)
Table 3. Relationships between Cytological HSIL and Clinical Factors on Univariate Analysis in 69 Patients with Normal Cervical
Cytology before SCT
Posttransplantation Cytological HSIL
P ValuePresence (n 5 16) Absence (n 5 53)
Age at transplantation, years, mean ± SD 44.1 ± 10.6 37.5 ± 11.9 .05
Hematologic diagnosis: leukemia, % (n) 87.5 (14) 96.2 (51) .58
Disease risk: high, % (n) 18.8 (3) 18.9 (10) .99
Donor source: unrelated HLA-matched, % (n) 43.8 (7) 20.8 (11) .07
aGVHD, % (n) 37.5 (6) 37.7 (20) .99
cGVHD, % (n) 50 (8) 41.5 (22) .55
Vulvovaginal cGVHD, % (n) 18.8 (3) 3.8 (2) .04
Stem cell source: peripheral blood, % (n) 18.8 (3) 22.6 (12) .74
Duration of innumosuppressive therapy, months, median (range) 10.5 (0-78) 12 (4-48) .26
Duration of follow-up, years, median (range) 11 (5-15) 10 (5-25) .79
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Transplantation in Patients with Normal
Cervical Smear before Transplantation
The relationships between cervical cytological
HSIL after transplantation and clinical factors in uni-
variate analysis in the 69 patients with normal cervical
smear before transplantation are delineated in Table 3.
Vulvovaginal cGVHD was significantly associated
with the prevalence of cervical cytological HSIL after
transplantation. Age at transplantation had a border-
line association with the prevalence of HSIL. In addi-
tion, donor source had a P value\.20. We included
these 3 variables with P\ .20 in the univariate analyses
in a multivariate logistic regression model to identify
independent risk factors for HSIL after transplanta-
tion before and after adjusting for confounding factors
(marital status, smoking history, menopause history,
HRT, and parity before transplantation). Results
from the multivariate analysis are presented in
Table 4. Before adjustment for the confounding
factors, older age at transplantation, unrelated HLA-
matched donor, and the presence of vulvovaginal
cGVHD were significantly associated with the preva-
lence of HSIL after transplantation. However, after
adjustment for these confounding factors, only unre-
lated HLA-matched donor and vulvovaginal cGVHD
were independent risk factors for HSIL after trans-
plantation, with the greatest risk in patients with vul-
vovaginal cGVHD (adjusted odds ratio [OR], 31.97;
95% CI, 1.33-769.42). Older age at transplantation
did not maintain its independent effect on HSIL after
transplantation.
We also evaluated risk factors for histologically
verified cervical dysplasia (CIN II or worse). On mul-
tivariate analysis, vulvovaginal cGVHD was the onlyTable 4. Relationships between Cytologic HSIL and Clinical Factor
C
OR 95
Age at transplantation 1.08 1.02
Source of donor (unrelated versus related HLA-matched) 6.74 1.45
Vulvovaginal cGVHD (presence versus absence) 11.88 1.17
*Adjusted for the confounding factors marital status, smoking history, parity bindependent risk factor significantly associated with
histological cervical dysplasia after adjusting for con-
founding factors (adjusted OR, 47.7; 95% CI, 1.83-
1234.65; P 5 .02).DISCUSSION
In developed countries, the estimated lifetime risk
of cervical CIN is 5%, that of invasive cervical cancer is
1%, and that of dying of cervical cancer is 0.3% [20]. In
Norway, 388,313 women age 15-69 years underwent
cervical cytological testing in 2008, and the overall
incidence of ASC-US, LSIL, and HSIL was 2.0%,
0.98%, and 0.46%, respectively (data from the
NCR). An increased risk for squamous intraepithelial
lesions (SILs), ranging from 7.3% to 49%, has been
reported in patients undergoing solid organ transplan-
tation [16,21,22]. A recent study on allo-SCT found
SIL in 43% of the patients (15 of 35), of which 34%
were HPV-related [14]. Another recent study found
a significantly higher rate of cytological abnormalities
in bone marrow transplant recipients than in the
general population both before transplantation (age-
adjusted OR, 2.2) and after transplantation (OR, 7.0)
[15]. To the best of our knowledge, the present study
has the largest number of patients and longest
follow-up time in a screening program for the presence
of CIN. The prevalences of ASC-US, LSIL, andHSIL
were 6.3%, 2.5%, and 3.8%, respectively, before allo-
SCT and 31.5%, 10.1%, and 27% after allo-SCT.
These values are significantly higher than those found
in the general population both before and after trans-
plantation and are in agreement with previous studies.
Several theories have been developed in an attempt
to explain the high incidence of abnormal cervicals on Multivariate Analysis
rude Adjusted*
% CI P Value OR 95% CI P Value
-1.16 .02 1.13 0.97-1.31 .12
-31.28 .02 11.61 1.12-120.8 .04
-120.37 .04 31.97 1.33-769.42 .03
efore transplantation, menopause history, and HRT.
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cogenic HPV likely plays a major role in the develop-
ment of cervical SIL. Indeed, higher prevalences of
HPV infection have been reported in transplant recip-
ients [16,23] and HIV-infected women [24] than in the
general population. Savani et al. [14] reported that
34% of their patients undergoing allo-SCT had
HPV-related SIL. Consistent with these previous
studies, the present study found that 38.9% (7 of 18)
of the cases of cervical SIL in our population were
HPV-related. It has been assumed that immunosup-
pression leads to an increased rate of infection with on-
cogenic HPV, reactivation of latent HPV, or impaired
ability to clear virus, thereby increasing the risk of cer-
vical cytological abnormalities and subsequent cervical
cancer. In addition, chemotherapy for the underlying
malignancy or malignancy-associated immunosup-
pression before transplantation may allow persistent
HPV replication or lead to cervical dysplasia in the
absence of HPV infection. These factors might explain
the higher prevalence of abnormal cervical smears in
our population compared with the general population
even before allo-SCT. The majority of our patients
with normal pretransplantation cervical smears
(63.8%) demonstrated cytological abnormalities
posttransplantation. These new cytological abnormal-
ities might either have been true new infections or
reactivations of latent HPV virus in the setting of
immunosuppression, as commonly occurs with other
viral infections, such as varicella zoster virus in bone
marrow transplantation [25].
Holowaty et al. [26], in a study of the natural his-
tory of cervical dysplasia, reported that the majority
of untreatedmild dysplasias regressed to yield a normal
smear within 2 years. However, the risk of progression
from moderate dysplasia was 16% within 2 years and
25% within 5 years. The excessive risk of cervical can-
cer associated with severe and moderate dysplasia was
greatest within 2 years of the initial dysplastic smear.
The authors suggested that moderate dysplasia may
represent a clinically useful distinction for progression
to severe dysplasia or worse. Thus, we focused on
those patients with normal pretransplantation cervical
cytology who demonstrated cytological HSIL post-
transplantation and identified independent risk factors
for those patients. After adjustment for confounding
factors, vulvovaginal cGVHD and unrelated HLA-
matched donor were the only independent risk factors
for developing cervical cytological HSIL in our
patients. Previous studies have identified GVHD as
a risk factor for secondary solid cancers after allo-
SCT. A recent multi-institutional cohort study of
28,874 allo-SCT recipients identified 189 solid malig-
nancies. Patients developed new solid cancers at twice
the rate expected based on the rate in the general
population, and the risk was 3-fold greater among
patients followed for 15 years or longer after trans-plantation [11]. GVHD was the main determinant of
the risk of squamous cell carcinomas, whereas total
body irradiation was the major risk factor for develop-
ing non–squamous cell carcinomas. Majhail et al. [27]
reported a 1.4-fold greater risk for secondary solid
cancer in allo-SCT recipients compared with the gen-
eral population. Chronic GVHD was an independent
risk factor for all solid cancers, especially cancers of
the oral cavity. Few previous studies have evaluated
risk factors for cervical cytological abnormalities in
allo-SCT recipients. Consistent with our findings in
the present study, Savani et al. [14] reported that
HPV-related cervical dysplasia was significantly
associated only with cGVHD requiring prolonged
($3 years) systemic immunosuppressive therapy in
long-term survivors of allo-SCT. GVHD is known
to result in mucosal lesions, which may act either inde-
pendently or synergistically with an HPV infection to
induce abnormal cytological development.
The present study demonstrates for the first
time that the use of an unrelated HLA-matched
donor may be an independent risk factor for cervical
HSIL in long-term allo-SCT survivors. Unrelated
HLA-matched donor transplants are reportedly associ-
atedwith an increased risk forGVHDamong allo-SCT
survivors [28]. Whether this is due to immunogenetic
factors or perhaps the immunosuppressive therapy for
GVHD disease that could compromise immune
surveillance of the development of malignant tumors,
or both, is not clear. After adjustment for GVHD and
duration of immunosuppressive therapy, unrelated
HLA-matched donor still remained a significant risk
factor for developing cervical HSIL in this study.
Our study has the limitations of being a registry-
based retrospective and single-center cohort study.
After routine gynecologic examination in our hospital
at 5 years posttransplantation, not all patients
underwent cervical cytology testing every 3 years
thereafter as was recommended. Thus, we might not
have captured all cases of cervical abnormalities in
the long-term follow-up. In addition, the number of
lifetime sexual partners (which might affect the inci-
dence of HPV infection and cervical dysplasia) was
not fully reported in the medical record for most of
the patients, and it was impossible to control for this
factor in our study. The strength of our study is that
a consistent myeloablastive regimen (busulfan/cyclo-
phosphamide) and a consistent GVHD prophylactic
regimen (cyclosporine/methotrexate) are readily
accessible to 99% of all patients. Moreover, our study
contained data on lifestyle risk factors, such as smoking
history, marital status, parity before transplantation,
menopause history, and HRT, which were adjusted
for in the multivariate analyses.
Notwithstanding these limitations, our findings
demonstrate a higher incidence of cervical cytological
abnormalities in allo-SCT recipients than in the
Biol Blood Marrow Transplant 18:747-753, 2012 753Cervical Dysplasia in Long-Term Allogeneic SCT Survivorsgeneral population, and that vulvovaginal cGVHD
and an unrelated HLA-matched donor are indepen-
dent risk factors for the development of cervical
HSIL posttransplantation in patients with normal cer-
vical cytology before transplantation. Our results
underscore the importance of regular surveillance of
these patients to allow early diagnosis and effective
management and to decrease the risk of cervical
carcinoma. It is also important to guide these women
after allo-SCT who are at high risk for cervical dyspla-
sia to practice safe sex, to reduce the risk for HPV
infection. Furthermore, HPV vaccination should be
considered in adolescents and young women who
have undergone allo-SCT and thus are at high risk
for cervical dysplasia.CONCLUSIONS
Allo-SCT survivors are at high risk for cervical
cytological abnormalities. Vulvovaginal cGVHD and
an unrelated HLA-matched donor are the only inde-
pendent risk factors for cervical HSIL after allo-SCT.
The importance of regular surveillance, including
gynecologic examinations and cervical cytological test-
ing, in these patients allows early diagnosis and effective
management of cervical abnormalities, thereby
decreasing the risk of developing cervical cancer.ACKNOWLEDGMENTS
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